Prof. Lang Bu | Immunity | Best Researcher Award

Posted on by Pencis

Prof. Lang Bu | Immunity | Best Researcher Award

Sun Yat-sen University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Prof. Lang Bu’s academic journey began with a focus on innate immunity, virus infections, and liver cancer, laying the foundation for groundbreaking research in signal transduction and tumor microenvironment. His passion for molecular biology and protein modifications has driven his career in precision medicine. His early education in these areas led him to specialize in innovative therapeutic strategies for combating cancer and viral diseases.

💼PROFESSIONAL ENDEAVORS

Prof. Bu currently serves as an Associate Researcher at the Institute of Precision Medicine in Sun Yat-sen University, where he contributes to cutting-edge research on innate immunity and viral infection. His professional experience spans consultancy projects and leadership in high-impact research. His work extends to industry collaborations, underscoring his connection between academic research and practical applications.

🔬CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNITY

Prof. Bu’s research has significantly contributed to the understanding of tumor immunology, particularly focusing on innate immunity, viral infections, and liver cancer. He utilizes advanced techniques to explore signal transduction pathways and immune response mechanisms. His work in post-translational modifications and DNA sequencing has paved the way for personalized treatments, offering insights into innovative therapeutic approaches for cancer and infectious diseases.

🌍IMPACT AND INFLUENCE

Prof. Bu’s research has influenced the fields of viral immunity, tumor biology, and cancer immunotherapy. With significant contributions to global health through published works in SCI and Scopus journals, his influence extends into clinical and global health solutions. Prof. Bu’s findings aim to address critical health issues, particularly in liver cancer and virus-related diseases, ensuring impactful global influence.

📚ACADEMIC CITES

Prof. Bu has a citation index of PMID: 39255795, with 18 published journals in SCI and Scopus-indexed journals. His work has established him as a respected researcher in the areas of innate immunity and virus infection, positioning him as a key figure in advancing the scientific community’s understanding of these critical areas.

🏆RESEARCH GRANTS AND FUNDING

Prof. Bu has successfully secured research funding to support his work in tumor microenvironment and genomic technologies. His ability to attract substantial research grants has enabled further exploration into personalized cancer therapies and advanced immunotherapies, advancing the application of precision medicine.

🛡️LEGACY AND FUTURE CONTRIBUTIONS

Prof. Bu’s legacy is grounded in advancing immune-based therapies and enhancing our understanding of tumor immunity. His ongoing research into innate immunity and viral infection mechanisms is expected to contribute to groundbreaking therapeutic strategies for cancer and infectious diseases.

📑NOTABLE PUBLICATIONS

“Targeting APT2 improves MAVS palmitoylation and antiviral innate immunity”

Authors: Bu, L., Wang, H., Zhang, S., Cheng, C., Guo, J.
Publication Year: 2024
Journal: Molecular Cell
Citations: 2

“High-fat diet promotes liver tumorigenesis via palmitoylation and activation of AKT”

Authors: Bu, L., Zhang, Z., Chen, J., Kuang, M., Guo, J.
Publication Year: 2024
Journal: Gut
Citations: 19

“Atypical inflammatory kinase IKBKE phosphorylates and inactivates FoxA1 to promote liver tumorigenesis”

Authors: Gao, B., Wu, X., Bu, L., Xie, W., Guo, J.
Publication Year: 2024
Journal: Science Advances
Citations: 3

“AMPK phosphorylates and stabilises copper transporter 1 to synergise metformin and copper chelator for breast cancer therapy”

Authors: Zhang, X., Jiang, Q., Su, Y., Xie, W., Guo, J.
Publication Year: 2023
Journal: British Journal of Cancer
Citations: 9

“AKT Blocks SIK1-Mediated Repression of STAT3 to Promote Breast Tumorigenesis”

Authors: Sun, Z., Jiang, Q., Gao, B., Li, J., Guo, J.
Publication Year: 2023
Journal: Cancer Research
Citations: 11

Prof. Zhiyi He | Immunology of Infections | Best Researcher Award

Posted on by Pencis

Prof. Zhiyi He | Immunology of Infections | Best Researcher Award

The First Affiliated Hospital of Guangxi Medical University | China.

Author Profile

Scopus

🎓EARLY ACADEMIC PURSUITS

Professor Zhiyi He embarked on his academic journey with a focus on respiratory medicine, excelling during his medical training. His dedication to advancing healthcare led him to pursue rigorous education and research, establishing a strong foundation for his future endeavors.

🩺PROFESSIONAL ENDEAVORS

Position: Professor and Doctoral Supervisor at The First Affiliated Hospital of Guangxi Medical University.

Roles:

  • Member of the Respiratory Society of the Chinese Medical Association.
  • Young Member of the Chinese Respiratory Society.
  • Member of the COPD Group of the Chinese Respiratory Society.
  • Chairman of the Respiratory Disease Branch of the Guangxi Medical Association.

🔬 CONTRIBUTIONS AND RESEARCH FOCUS ON IMMUNOLOGY OF INFECTIONS

Professor Zhiyi He’s research is pivotal in addressing chronic respiratory diseases, with a particular emphasis on:

  • Chronic Obstructive Pulmonary Disease (COPD).
  • Advancing diagnostic and therapeutic approaches for respiratory illnesses.
  • Promoting interdisciplinary research to integrate cutting-edge treatments.

🌍IMPACT AND INFLUENCE

Professor He’s contributions have significantly shaped respiratory medicine, not only within Guangxi but across China. As the Chairman of the Respiratory Disease Branch of the Guangxi Medical Association, he has spearheaded initiatives to improve healthcare accessibility and quality for patients with chronic respiratory conditions.

📚ACADEMIC CITATIONS

With numerous publications in high-impact journals, Professor Zhiyi He is widely cited in the fields of respiratory medicine and clinical research. His work has influenced academic peers and practitioners, reflecting his stature as a thought leader in his domain.

🦠LEGACY AND FUTURE CONTRIBUTIONS

Achievements: Named the 2020 Outstanding Scholar of Guangxi Colleges and Universities, a testament to his enduring contributions to academia and healthcare.

Vision: Professor He aims to continue driving innovation in respiratory medicine through mentorship, research, and clinical practice, leaving a lasting legacy for future generations of medical professionals.

📑NOTABLE PUBLICATIONS 

“Multiple pathogen infections accompanied with ocular pathologies in a patient with high-titer Anti-IFN-γ autoantibodies: a case report” 

Authors: Wu, S., Liang, S., Liang, H., Li, X., He, Z.
Journal: BMC Infectious Diseases
Publication Year: 2024

“Effect of high-dose N-acetylcysteine on exacerbations and lung function in patients with mild-to-moderate COPD: a double-blind, parallel group, multicentre randomised clinical trial” 

Authors: Zhou, Y., Wu, F., Shi, Z., Liu, S., Zhao, Z.
Journal: Nature Communications
Year: 2024

“Polyphyllin B inhibited STAT3/NCOA4 pathway and restored gut microbiota to ameliorate lung tissue injury in cigarette smoke-induced mice” 

Authors: Wang, Q., He, Z., Zhu, J., Yang, L., Yang, H.
Journal: BMC Biotechnology
Year: 2024

“Multiple intracellular pathogen infections with ocular pathologies associated with adult-onset immunodeficiency due to anti-interferon-γ autoantibodies: a case report” 

Authors: Ning, Y., Yu, Q., Liang, H., Liang, X., He, Z.
Journal: BMC Infectious Diseases
Year: 2024

“Mechanism of cigarette smoke in promoting small airway remodeling in mice via STAT 3 / PINK 1-Parkin / EMT” 

Authors: Wei, Y., Li, Q., He, K., Li, M., He, Z.
Journal: Free Radical Biology and Medicine
Year: 2024

Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

Posted on by Pencis

Prof. Shu-Ching Hsu | Immunology of Infections | Best Researcher Award

Prof. Shu-Ching Hsu, National Health Research Institute/National Institute of Infectious Diseases and Vaccinology, Taiwan.

Prof. Shu-Ching Hsu is an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan. She earned her Ph.D. in Molecular Immunology and Signal Transduction from National Taiwan University and specializes in immunology, stem cell biology, and vaccine development. Prof. Hsu is widely recognized for her pioneering research on immune suppression, neutrophil biology, and the development of humanized mouse models to study immune responses in infectious diseases. Her work has significantly advanced immunotherapy, drug discovery, and our understanding of immune mechanisms in disease progression. She was honored with the Best Researcher Award for her exceptional contributions to the field of immunology and infectious diseases.

Author Profile

Scopus

🏫EARLY ACADEMIC PURSUITS

Dr. Shu-Ching Hsu earned her Ph.D. in Molecular Immunology and Signal Transduction from the Graduate Institute of Microbiology, National Taiwan University (1995–2000). Prior to this, she completed her M.S. in Molecular Biology and Immunology at National Yang-Ming University (1993–1995) and her B.S. in Microbiology from Soochow University (1989–1993).

💼 PROFESSIONAL ENDEAVORS

Dr. Shu-Ching Hsu has extensive professional experience in both research and academia. She is currently an Associate Investigator at the National Institute of Infectious Diseases and Vaccinology (NIIDV), NHRI, Taiwan (2013–present) and holds Associate Professor positions at National Chung Hsing University, National Defense University, and Kaohsiung Medical University (2013–present). Prior to her current roles, she served as an Assistant Investigator at the Vaccine Research and Development Center, NHRI, Taiwan (2005–2013). Dr. Hsu also completed two postdoctoral fellowships: one at Tulane University, USA (2002–2005) and another at Academia Sinica, Taiwan (2000–2002).

🔬RESEARCH INTERESTS

Dr. Shu-Ching Hsu’s research interests focus on human neutrophil biology and progenitor cell differentiation, as well as the development of humanized mouse models for advancing immunotherapy and drug discovery. She is also deeply engaged in understanding the mechanisms of immune suppression, particularly through myeloid-derived suppressive cells (MDSCs), and their role in disease progression. Additionally, Dr. Hsu explores stem cell-based therapies aimed at addressing infectious diseases, cancer, and various immune disorders.

🧠TECHNICAL SKILLS

Dr. Shu-Ching Hsu possesses expertise in stem cell biology, particularly in the development and use of humanized mouse models for immunotherapy and drug discovery. She is proficient in neutrophil biology, cell signaling, and understanding immune suppression mechanisms. Additionally, Dr. Hsu is skilled in the genetic modification of hematopoietic stem cells (HSCs) and the creation of stem cell-derived immune cell platforms for research and therapeutic applications.

📑 NOTABLE PUBLICATIONS 

“IL-10RA governs the expression of IDO in the instruction of lymphocyte immunity” 

Authors: Tai, T.-S., Hsu, D.-W., Yang, Y.-S., Wu, C.-H., Hsu, S.-C.
Publication Year: 2024
Citations: 0

“Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein” 

Authors: Chiu, Y.-S., Wu, K.-J., Yu, S.-J., Wang, Y., Chen, Y.-H.
Publication Year: 2023
Citations: 1

“Correction: Metronomic chemotherapy prevents therapy-induced stromal activation and induction of tumor-initiating cells” 

Authors: Chan, T.-S., Hsu, C.-C., Pai, V.C., Weaver, V.M., Tsai, K.K.
Publication Year: 2023
Citations: 0

“The potential of adoptive transfer of γ9δ2 T cells to enhance blinatumomab’s antitumor activity against B-cell malignancy” 

Authors: Chen, Y.-H., Wang, Y., Liao, C.-H., Hsu, S.-C.
Publication Year: 2021
Citations: 4

“Index of cancer-associated fibroblasts is superior to the epithelial–mesenchymal transition score in prognosis prediction” 

Authors: Ko, Y.-C., Lai, T.-Y., Hsu, S.-C., Lin, C.-Y., Lin, S.-F.
Publication Year: 2020
Citations: 19

“Downregulation of α-Synuclein Protein Levels by an Intracellular Single-Chain Antibody” 

Authors: Chen, Y.-H., Yu, S.-J., Wu, K.-J., Hoffer, B.J., Wang, Y.
Publication Year: 2020
Citations: 7

Ms. Ziyi Wang | Immunology of Infections | Best Researcher Award

Posted on by Pencis

Ms. Ziyi Wang | Immunology of Infections | Best Researcher Award

Ms. Ziyi Wang, Wenzhou Medical University, China.

Ms. Ziyi Wang is a researcher specializing in the immunology of infections, with a focus on understanding how the immune system responds to various pathogens. Currently pursuing a Master’s degree in Epidemiology and Medical Statistics at Wenzhou Medical University, she has made significant contributions to the study of infection-related biomarkers and immune responses. Ziyi’s research has earned her the Best Researcher Award, recognizing her innovative work in identifying immune mechanisms and biomarkers that could inform better diagnostics and treatments for infectious diseases. Her dedication to advancing the field has led to her publication of multiple research articles in peer-reviewed journals.

Professional Profiles

Scopus Profile

📚Education

Ms. Ziyi Wang is currently pursuing a Master’s degree in Epidemiology and Medical Statistics at Wenzhou Medical University in Wenzhou, Zhejiang, China. Her academic focus includes researching biomarkers related to diabetes and its complications, particularly in the context of diabetic retinopathy. She has gained a strong foundation in statistical analysis, epidemiological research methods, and disease modeling, with an emphasis on applying these skills to medical and public health issues. Her studies also integrate practical research experience, contributing to her ongoing work in diabetes-related research.

💼Experience

Ms. Ziyi Wang is currently conducting research on biomarkers for diabetic retinopathy (DR), with a specific focus on the role of plasma OA levels. Her work aims to investigate how OA levels could serve as a potential biomarker for early detection and effective management of DR, a common and vision-threatening complication of diabetes. By employing various statistical methods and analytical approaches, her research seeks to better understand the relationship between OA levels and DR risk, contributing to improved diagnostic models and potential clinical interventions for patients with diabetes.

🔬Research Interest

Ms. Ziyi Wang’s research interests focus on biomarkers for diabetic retinopathy (DR), with a particular emphasis on their potential for early detection and effective management of the condition. She is dedicated to exploring the underlying mechanisms of diabetes complications and how specific biomarkers can be utilized for improved diagnosis and treatment. Additionally, her research seeks to identify and explore new treatment targets for DR, aiming to contribute to the development of more targeted and effective therapeutic strategies for managing this vision-threatening complication of diabetes.

👩‍🏫Technical Skills

Ms. Ziyi Wang is proficient in a wide range of technical skills, including statistical analysis, epidemiological modeling, and biomarker detection. She applies advanced statistical methods to analyze complex data and model disease patterns, particularly in the context of diabetes and its complications. Her expertise in biomarker detection allows her to identify key indicators that contribute to the early detection and management of conditions like diabetic retinopathy. Additionally, Ziyi is well-versed in various research methodologies, ensuring the rigorous design, execution, and analysis of her studies to produce reliable and impactful scientific results.

🎤Academic Citations

Ms. Ziyi Wang has published three articles in academic journals, making significant contributions to the field of diabetes research, particularly in the area of biomarkers for diabetic complications. Her research focuses on identifying key biomarkers that can aid in the early detection and management of diabetes-related complications, such as diabetic retinopathy. These publications have helped expand the understanding of the role of biomarkers in diabetes and have provided valuable insights into potential diagnostic tools and treatment strategies, further advancing the knowledge in this critical area of medical research.

📑Top Note Publications

Title: The risk of dyslipidemia on PLHIV associated with different antiretroviral regimens in Huzhou

Authors: Wang, Y., Yang, Z., Li, J., Jin, M., Mao, G.
Publication Year: 2024
Citations: 0

Title: Impact of sarcosine on diabetic retinopathy: Findings based on weighted gene co-expression network analysis and machine learning techniques

Authors: Che, M., Xia, Z., Jiang, D., Zheng, C., Mao, G.
Publication Year: 2023
Citations: 0

Title: Title: Anemia is independently associated with mortality in people living with human immunodeficiency virus/acquired immune deficiency syndrome: A propensity score matching-based retrospective cohort study in China

Authors: Jin, M., Wang, Y., Li, J., Yang, Z., Mao, G.
Publication Year: 2023
Citations: 3